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Abstract
In this study, the serological status of the southern Greek popu-
lation in the 1–10-year, 11–20-year, 21–30-year and 31–40-year
age groups with regard to Sabin vaccine strains and a collection
of 15 recombinant and four non-recombinant poliovirus vaccine
strains was determined. For all three poliovirus types, the high-
est neutralization test (NT) titres were observed in the 1–10-
year age group, indicating a good response to vaccination. In
general, the serological status of the population of southern
Greece with regard to poliovirus is better for types 1 and 2
than for type 3. The presence of the lowest NT titre in the 21–
30-year age group against poliovirus type 3 suggests the need
for a booster dose of monovalent Sabin3 vaccine to ensure per-
sonal and herd immunity.
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Since the 1960s, poliovirus, the causal agent of poliomyelitis,
has been effectively controlled by the use of inactivated
poliovirus vaccine (IPV) or live attenuated oral poliovirus
vaccine (OPV), which is composed of attenuated strains of
each of the three serotypes (Sabin1, Sabin2, and Sabin3) [1].
By 1964, OPV was the vaccine that had been adopted
throughout most of the world, because of several advantages
over IPV, such as: simplicity of administration, induction of
mucosal immunity and neutralizing antibodies, and low cost.
Since the Poliomyelitis Eradication Initiative was launched in
1988, great progress has been made in stopping the trans-
mission of wild-type poliovirus and in achieving global certiﬁ-
cation of eradication by 2005 [2]. The number of
poliomyelitis cases due to infections with wild-type polio-
viruses decreased from an estimated 350 000 in over 125
endemic countries in 1988 to just 1310 in four countries in
2007 [3]. Poliomyelitis transmission has been interrupted in
the American, European and Western Paciﬁc regions, and by
the end of 2002 more than 180 countries and territories had
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been declared to be polio-free. At present, the virus remains
endemic in four countries: Afghanistan, India, Nigeria, and
Pakistan [2].
The eradication strategies recommended by the WHO
include: (i) high routine infant immunization coverage with at
least three doses of OPV plus a dose at birth in polio-ende-
mic countries; (ii) national immunization days targeting all
children aged <5 years; (iii) acute ﬂaccid paralysis surveillance
and laboratory investigations; and (iv) mop-up immunization
campaigns with OPV to interrupt ﬁnal chains of transmission
[2].
In the late 1990s it was recognized that polio outbreaks
can be caused by circulating live-attenuated vaccine viruses
(Sabin strain) that have reverted and re-acquired neuroviru-
lence. By late 2005, six outbreaks caused by such circulating
vaccine-derived polioviruses (VDPVs), had been documented.
Moreover, in rare cases (one case per 750 000 primary vacc-
inees), OPV strains have been implicated in vaccine-associ-
ated paralytic poliomyelitis [4–7].
Emerging concerns, such as the vaccine-associated para-
lytic poliomyelitis cases and the isolation of VDPV in a num-
ber of countries, prompted the WHO, in its 2004–2008
strategic plans, to recommend cessation of OPV administra-
tion as soon as possible after interruption of wild-type polio-
virus circulation and continuing schedules of immunization,
mainly with IPV [8].
OPV was introduced into Greece in 1964, and a standard
vaccination schedule was initiated, including four doses at
the ages of 2, 4, 6 and 18 months, with a booster dose at
4–6 years. This vaccination schedule has led to the elimina-
tion of indigenous cases of poliomyelitis since 1982 [9].
However, since 2005, Greece has switched to the exclusive
use of IPV, like most polio-free countries.
In this study, the immunity level of the southern Greek
population in the 1–10-year, 11–20-year, 21–30-year and 31–
40-year age groups was measured against Sabin vaccine
strains and a collection of 15 recombinant and four non-
recombinant OPV derivatives. The study was carried out in
2008–2009, and the serum samples were collected from
regions of southern Greece. The serotypes of all OPV deriv-
atives were determined by microneutralization assay with
type-speciﬁc rabbit antisera (RIVM, Bilthoven, The Nether-
lands) according to the enclosed instructions and using stan-
dard procedures [10].
The level of immunity of the human population against
poliovirus types 1, 2 and 3 was determined with a microneu-
tralization assay, according to the WHO guidelines. Pooled
sera (40 mixed serum samples) were used from each age
group for the neutralization test (NT) [11]. Serum pools
were diluted 1 : 10 in MEM, heat-inactivated for 50 min at
56C, diluted two-fold from 1 : 10 to 1 : 1280, and incu-
bated in duplicate for 1 h at 37C with 100 50% tissue cul-
ture infective doses with each one of the 19 OPV derivatives
as well as with the Sabin vaccine strains (Sabin1, Sabin2, and
Sabin3). Finally, a cell suspension containing 104 Hep2 cells/
0.1 mL was added. Cell and virus controls were included in
each batch. The plates were examined daily (3–5 days) for
the development of cytopathic effect. When the virus con-
trols showed complete cytopathic effect, the ﬁnal results
were recorded 24 h later. The highest dilution of serum pool
that protected the cultures was recorded. Results were
expressed as log10 reciprocal titres (log10 titre 1 : 10 = 1).
Student’s t-test (paired samples test) was used to compare
the mean NT titres of four age groups (1–10, 11–20, 21–30
and 31–40 years) against each Sabin vaccine strain (Sabin1,
Sabin2, or Sabin3) with those against same serotype OPV
derivatives. A one-way ANOVA test (Duncan’s multiple
range test) was used to compare the mean NT titres against
the Sabin vaccine strain and OPV derivatives of the same
serotype between the 1–10-year, 11–20-year, 21–30-year
and 31–40-year age groups.
Table 1 shows the serotype and the recombination site
of each of the 19 OPV derivatives identiﬁed in previous
studies [12–17]. The serotype of OPV derivatives was
identiﬁed as P1 for ﬁve, as P2 for six, and as P3 for eight.
The majority of OPV derivatives were characterized as
OPV-related polioviruses displaying <1% divergence from
the VP1 region of the reference Sabin vaccine strain. How-
ever, an OPV derivative of serotype 1 was characterized as
VDPV in a previous study [12]. Speciﬁcally, it revealed
1.87% divergence from the VP1 region of reference strain
Sabin1 and a recombination event between the Sabin1
vaccine strain and a member of enterovirus group C in the
2A genomic region.
Table 2 shows the statistical analysis of the log10 recipro-
cal NT titres against Sabin vaccine strains and OPV deriva-
tives. The population of the 1–40-year age group shows
signiﬁcantly lower NT titres against two Sabin1 derivatives
(742 and 522) in comparison with the Sabin1 vaccine strain.
No signiﬁcant differences in NT titres were observed for
Sabin2 and Sabin3 derivatives in comparison with the Sabin2
and Sabin3 vaccine strains, respectively.
A sequential decrease in NT titre was observed from
the 1–10-year age group to the 11–20-year and 21–30-year
age groups in all three poliovirus types (P1, P2, and P3).
Speciﬁcally, a signiﬁcant decrease was observed from the 1–
10-year to the 11–20-year age group for poliovirus type 1
and from the 1–10-year age group to the 11–20-year and
21–30-year age groups for poliovirus types 2 and 3. An
increase in NT titre was observed from the 21–30-year to
CMI Research Notes 1673
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1669–1675
the 31–40-year age group for poliovirus types 1 and 3, but
not for poliovirus type 2. However, this increase was signif-
icant only for poliovirus type 3. For all three types, the
highest NT titres were observed in the 1–10-year age
group, indicating a good response to vaccination. The low-
est NT titre was observed in the 21–30-year age group
TABLE 1. The serotype, the
recombination type and the
recombination sites of all oral
poliovirus vaccine (OPV) deriva-
tives
Serotype 1 (P1) Serotype 2 (P2) Serotype 3 (P3)
742
S1/S3/S2a (2A/2C)b
This study
I34
S2/S1/S2/S1 (2C/3D/3D)
Karakasiliotis et al. (2005) [13]
EPC
S3/S2/S3 (2C/3D)
Paximadi et al. (2007) [16]
7/b/97
S1/EVCc (2A)
Dedepsidis et al. (2007) [12]
EP9
S2/S1 (3A)
Paximadi et al. (2006) [14]
EPB
S3/S2/S3 (2C/3D)
Paximadi et al. (2007) [16]
522
S1 (non-recombinant)
This study
EP12
S2/S1 (3D)
Paximadi et al. (2006) [14]
738
S3/S2/S1 (3C/3D)
This study
II
S1 (non-recombinant)
This study
ID
S2/S1 (3C)
Karakasiliotis et al. (2004) [15]
584
S3/S2/S1 (2C/3D)
This study
152
S1 (non-recombinant)
This study
IF
S2/S1 (3D)
Karakasiliotis et al. (2004) [15]
EPA
S3/S2/S3 (2C/3D)
Paximadi et al. (2007) [16]
8001
S2 (non-recombinant)
This study
K/2002
S3/S2 (VP1)
Dedepsidis et al. (2008) [17]
EP16
S3/S2 (2C)
Paximadi et al. (2006) [14]
EP23
S3/S1 (2C)
Paximadi et al. (2006) [14]
All isolates were characterized as OPV-related polioviruses except for one, which was characterized as a vaccine-
derived poliovirus strain (VDPV). The recombination sites of some OPV derivatives were identiﬁed previously by our
group (references are indicated).
aThe recombinations of OPV-related polioviruses are among Sabin vaccine strains (S1, Sabin1; S2, Sabin2; S3, Sabin3).
bRecombination sites are located in the 2A, 2C, 3A, 3C, 3D or VP1 genomic regions.
cIsolate 7/b/97 showed a recombination event between Sabin1 vaccine strain and a member of enterovirus group C
in the 2A genomic region. Moreover, it revealed 1.87% divergence from the VP1 region of reference strain Sabin1
and was characterized as VDPV.
TABLE 2. Statistical analysis of the log10 reciprocal neutralization test (NT) titres against Sabin vaccine strains and oral polio-
virus vaccine derivatives
Serotype Virus strain
Mean values of log10 reciprocal
NT titres of four age groups
(1–10, 11–20, 21–30 and 31–40
years) against each poliovirus
straina
Mean values of log]0 reciprocal NT titres of each age group
(1–10,11–20,21–30 or 31–40 years) against polioviruses
of the same serotypeb
1–10 11–20 21–30 31–40
1 Sabinl 2.80 3.00 (p 1.0) 2.45 (p 0.087) 2.10 (p 0.087) 2.40 (p 0.087)
742 2.35 (p 0.014)
7/b/97 2.80 (p l.0)
522 2.35 (p 0.014)
II 2.42 (p 0.080)
152 2.20 (p 0.066)
2 Sabin2 2.35 3.02 (p 1.0) 2.54 (p 1.0) 2.16 (p 1.0) 2.16 (p 1.0)
134 2.35 (p l.0)
EP9 2.42 (p 0.761)
EP12 2.58 (p 0.215)
ID 2.50 (p 0.182)
IF 2.50 (p 0.182)
8001 2.58 (p 0.058)
3 Sabin3 2.27 2.99 (p 1.0) 2.24 (p 1.0) 1.63 (p 1.0) 1.86 (p l.0)
EPC 2.42 (p 0.495)
EPB 2.12 (p 0.182)
738 l.97 (p 0.092)
584 2.27 (p l.0)
EPA 2.12 (p 0.182)
K/2002 l.97 (p 0.092)
EP16 2.27 (p l.0)
EP23 2.12 (p 0.182)
aMeans which are in italics have signiﬁcant differences according to Student’s t-test.
bMeans which are in italics in each poliovirus serotype have no signiﬁcant differences according to ANOVA test.
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against poliovirus type 3. This indicates an unsatisfactory
level of immunity against poliovirus type 3 in young adults.
These results are consistent with those of some previous
studies [18–20].
In general, the serological status of the population of
southern Greece with regard to poliovirus is better for
types 1 and 2 than for type 3. The presence of the lowest NT
titre in the 21–30-year age group against poliovirus type 3
suggests the need for a booster dose of monovalent Sabin3
vaccine to ensure personal and herd immunity. Moreover, the
higher NT titres of the 31–40-year age group against poliovi-
ruses 1 and 3 than those of the 21–30-year age group could
be attributed to the acquisition of antibodies following natural
infection with circulating poliovirus strains of types 1 and 3
during the ﬁrst 10 years of their life (time period: 1967–
1977). Moreover, a booster effect from babies to their par-
ents could contribute to the rise in NT titres observed in the
31–40-year age group. In contrast, the 21–30-year and 31–40-
year age groups displayed the same NT titres against polio-
virus strains of type 2, and this could be explained by the
earlier eradication of poliovirus type 2 than of types 1 and 3
from Greece and worldwide, as their worldwide transmission
was successfully interrupted after 1999 [21].
The existence of circulating VDPVs, their ability to pro-
duce outbreaks and the fact that they exhibit pathogenicity
similar to that of wild-type strains has signiﬁcantly changed
the risk–beneﬁt analysis associated with the ﬁnal stages of
the polio eradication campaign. It has become obvious that
the emergence of populations of unvaccinated individuals fol-
lowing OPV cessation could risk restarting a polio pandemic
caused by either circulating VDPV or wild-type polioviruses.
Today, following the replacement of OPV by IPV in most
developed countries, well-maintained herd immunity is a pri-
ority. It is tempting to assume that the changes in antigenic
properties frequently observed in OPV derivatives represent
a selection of viral variants that are less prone to be neutral-
ized by human antibodies. Taking into consideration that IPV
does not induce the same immunity as OPV, the need for
immunological studies in all age groups is urgent in order to
avoid epidemics due to the circulation of highly evolved OPV
derivatives and the importation of wild-type polioviruses
from endemic countries.
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